ANALEE FISH: Open Payments
NPI 1407405111 · REXBURG, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$835 in 44 payments from 21 companies in 2025. Trend: 2023 $562 · 2024 $1,013 · 2025 $835
Food & beverage: $835
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $139 |
| Vanda Pharmaceuticals Inc. | 4 | $102 |
| Lilly USA, LLC | 6 | $96 |
| Novo Nordisk Inc | 3 | $53 |
| GlaxoSmithKline, LLC. | 2 | $42 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Chiesi USA, Inc. | 1 | $33 |
| PFIZER INC. | 2 | $32 |
Products named: FANAPT, VRAYLAR, MOUNJARO, UBRELVY, TRELEGY ELLIPTA, XIFAXAN, VOQUEZNA, Veozah.
Industry payments across ID — which companies pay providers there.
